Context Therapeutics Buys Out CT-202 Royalty Obligations
PHILADELPHIA, PA — Context Therapeutics (Nasdaq: CNTX) amended its licensing agreement with BioAtla (Nasdaq: BCAB) to eliminate future milestone and royalty payments tied to its CT-202 cancer program, a move …
Context Therapeutics Buys Out CT-202 Royalty Obligations Read More